Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
about
Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculationTrial Watch-Immunostimulation with cytokines in cancer therapyRegional therapies for in-transit diseaseTreatment of Adult Soft Tissue Sarcomas: An OverviewNifedipine improves blood flow and oxygen supply, but not steady-state oxygenation of tumours in perfusion pressure-controlled isolated limb perfusion.In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.Effects of tumour necrosis factor alpha and melphalan on the cytokine production of circulating T cells in patients with cancer.Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusionsIsolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicityLack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin.Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusionLack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.Lower limb function and quality of life after ILP for soft-tissue sarcoma.Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.Trial watch: Immunostimulatory cytokines in cancer therapy.20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose mattersIsolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicineThe pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.Integrin targeted delivery of chemotherapeuticsNovel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.Solid tumor therapy: manipulation of the vasculature with TNF.Classification of current anticancer immunotherapiesLong-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremityLimb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasmsA review of controversies in the management of soft tissue sarcomas.Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring systemSystemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.Soft tissue and bone sarcoma group, 25th anniversary meeting on sarcomas, april 5-7, 2001, aarhus, denmark.
P2860
Q21245599-A610F0BE-31F8-45AA-92BD-B0317A7E2D1CQ28078725-AD716353-FE88-4976-BE4B-FB0719AF0E37Q28087553-136C27E7-D722-4596-9081-CF264CFC1B82Q28088685-3E0114B0-5F29-4C01-9BFA-855880E8B2DEQ30871587-ED615D8D-E2F6-428C-8677-133A447D58E1Q33177384-FCBB894B-4989-49CA-8619-95C83B8BD005Q33178110-00A7B502-DC11-47A1-B54F-C331E81876B4Q33178477-F7B2A4F8-FB21-40E7-AB69-1AEC0AE755F3Q33178607-59D0332F-76BB-413C-9FDE-A86B214F0447Q33180038-32654DB9-440F-4004-919F-951CEE2279FAQ33180138-21321968-B700-44E6-9253-56AE74E79F7BQ33180936-8640063B-EAB2-4A5D-A456-D659865CCD6BQ33181229-EB399C24-07C0-4165-BE2C-2C0E869EDF8AQ33181472-765695AB-8771-4C63-A4E7-9DB64F33CB24Q33183242-3B286238-A01A-49EA-BEED-6182BE3D9E24Q33183585-CD621CAB-0C1E-49C0-B55D-7551E168D92DQ33183884-3A0AC12D-6270-4DDA-8975-00B31FB33776Q33186209-3F12DFDB-6F31-4F7C-A156-469962B210EAQ33204006-1B850A38-B562-40EA-90E7-A78C05F85233Q33209414-4180F448-235C-4394-928E-B2802C92F54AQ33263624-3BB8E3EB-B268-461D-A11A-9B0F2021B7CAQ33309291-73A94D79-DF72-45E3-B127-54A23FC359ECQ33560777-8651F3B2-5538-4218-A2F8-B7D70FDA74C6Q33605532-47339253-9C03-40EC-BE94-D7DF4097A955Q33607479-92C7A6C1-79D6-409B-8744-9270B2727892Q33880165-58012977-2BF0-4748-9CD9-786DE41AF862Q34006197-2F08EC8B-1D3A-42ED-BE7A-5E0DBDFCC6D7Q34054797-A0294839-2A92-4A92-B99C-4EFF347AB1BEQ34419681-BF22E273-DD6B-46E8-BAD6-0726D76E78B6Q34655297-ECBB4F7D-F87A-4171-A9F2-F569144F394EQ34912725-61828C5C-DDE3-4EAB-9CF9-7BCB0CEE5562Q35049589-F17B753C-A196-474E-A1E4-7E9021FEC728Q35142322-0001080B-EB86-4F79-87C5-560F8C92167DQ35149637-92DAB1BD-ABC0-406B-B224-7A874ED5F1CFQ35880851-49C4262C-91AC-452D-B93A-B201EDB73ED8Q35891783-1E76EA26-99EE-4351-8814-7C7CD6394002Q36095822-EC66E2C0-67A5-413F-A5C0-99E6390408BBQ36514467-DA600B31-FC16-40A0-B4FC-7B0F380BCD47Q36673686-A74DFF7F-CE79-4BDE-BE96-C5021AA873CDQ36690899-AE420A5D-165A-44F1-AB6B-F363D6B24A0E
P2860
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Isolated limb perfusion with h ...... sarcomas: a multicenter trial.
@en
type
label
Isolated limb perfusion with h ...... sarcomas: a multicenter trial.
@en
prefLabel
Isolated limb perfusion with h ...... sarcomas: a multicenter trial.
@en
P2093
P1476
Isolated limb perfusion with h ...... sarcomas: a multicenter trial.
@en
P2093
A M Eggermont
A N van Geel
F J Lejeune
H J Hoekstra
H Schraffordt Koops
P304
P356
10.1200/JCO.1996.14.10.2653
P407
P577
1996-10-01T00:00:00Z